Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 13, 2024 (2 years ago)

Vasopressin Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Subpotent product in addition to having out-of-specification results for impurities.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Vasopressin Injection, USP, 200 Units per 10 mL (20 Units per mL), 10 mL Multiple-Dose Vial, Rx only, For Intravenous Infusion, American Regent, Inc., Shirley, NY 11967, NDC 0517-1030-01

Affected NDC 0517-1030-01

Compare with the code on your package — it is the most precise check available.

Drug: Vasopressin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Vasopressin
NDC 00517-1030
20 [USP'U]/mL Injection, Solution
Intravenous
American Regent, Inc. Rx
Recalling firm
American Regent, Inc.
NDC code
0517-1030-01
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0507-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Vasopressin recalls

See all
Class II · Moderate risk

Vasopressin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-9647-12 D-0819-2026
Class II · Moderate risk

Vasopressin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-9640-12 D-0811-2026

Other recalls by American Regent, Inc.

All 2024 recalls
Class I · High risk

Epinephrine Injection

Presence of Particulate Matter and Lack of Assurance of Sterility. Particulate matter identified as nylon, cellulosic, acrylic, polyethylene and glass and broken and leaking vials.

Ongoing Sterility / contamination American Regent, Inc. NDC 0517-3030-01 D-0865-2026
Class I · High risk

Papaverine HCl Injection

Presence of Particulate Matter: Product contaminated with particulate matter identified as glass and/or paraformaldehyde

Ongoing Particulate / foreign matter American Regent, Inc. NDC 0517-4002-01 D-0800-2026